Zygolide gives equine vets a new generic pergolide option

Zygolide gives equine vets a new generic pergolide option for PPID

A new FDA-approved generic pergolide product, Zygolide, is now being promoted to equine clinicians and pet parents as a daily treatment option for horses with pituitary pars intermedia dysfunction, or PPID. FDA approved Zygolide on January 9, 2026, as the first generic pergolide tablet for control of PPID clinical signs in horses, finding it bioequivalent to Prascend, the long-established brand product first approved in 2011. The product, marketed by Dechra, is a 1 mg tablet available in 60- and 160-count cartons, with messaging centered on peppermint flavoring, half-scored 360-degree tablet design, and cost-effectiveness. The Horse promotional carousel published March 4, 2026, highlights those same points, including support for consistent daily use and pricing-based value claims. (fda.gov)

Why it matters: For veterinary professionals, the significance is less about a novel mechanism and more about access, adherence, and long-term management. PPID is a lifelong disease, so a lower-cost generic could improve treatment continuity for pet parents facing chronic medication expenses. Zygolide’s label mirrors pergolide’s established dosing framework, with a starting dose of 2 mcg/kg once daily and titration up to 4 mcg/kg daily, while the tablet scoring may help with dose adjustment. At the same time, clinicians will still need to counsel clients on handling precautions, appetite-related adverse effects, and the importance of monitoring response with clinical signs and endocrine testing rather than assuming interchangeability solves adherence on its own. (animaldrugsatfda.fda.gov)

What to watch: Watch for how quickly Zygolide gains formulary and pharmacy traction, whether pricing meaningfully shifts long-term PPID management, and how equine vets position it against established branded and compounded pergolide use. (thehorse.com)